|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 43.23 USD | -1.91% |
|
-2.00% | -20.17% |
| 01-17 | Top Premarket Gainers | MT |
| 01-17 | Goldman Sachs Upgrades MoonLake Immunotherapeutics to Buy From Neutral, Adjusts Price Target to $82 From $62 | MT |
| Capitalization | 2.73B 2.63B 2.49B 2.19B 3.9B 237B 4.33B 29.62B 10.99B 98.28B 10.22B 10.01B 415B | P/E ratio 2024 * |
-24.6x | P/E ratio 2025 * | -16.7x |
|---|---|---|---|---|---|
| Enterprise value | 2.31B 2.23B 2.11B 1.86B 3.3B 200B 3.67B 25.07B 9.3B 83.21B 8.65B 8.48B 351B | EV / Sales 2024 * |
-
| EV / Sales 2025 * | - |
| Free-Float |
84.77% | Yield 2024 * |
-
| Yield 2025 * | - |
More valuation ratios
* Estimated data
More news
More recommendations
More press releases
| 1 day | -1.91% | ||
| 1 week | -2.00% | ||
| Current month | -6.00% | ||
| 1 month | -6.66% | ||
| 3 months | -19.78% | ||
| 6 months | -2.31% | ||
| Current year | -20.17% |
1 week
42.65
48.54
1 month
41.2749.06
Current year
41.2756.00
1 year
37.5564.00
3 years
4.2564.98
5 years
4.2564.98
10 years
4.2564.98
| Director | Title | Age | Since |
|---|---|---|---|
Jorge da Silva
CEO | Chief Executive Officer | 48 | 04/04/2022 |
Kristian Reich
CTO | Chief Tech/Sci/R&D Officer | 59 | 04/04/2022 |
| Director of Finance/CFO | 37 | 04/04/2022 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jorge da Silva
BRD | Director/Board Member | 48 | 04/04/2022 |
Simon Sturge
CHM | Chairman | 66 | 04/04/2022 |
Spike Loy
BRD | Director/Board Member | 44 | 04/04/2022 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.23% | 0 M€ | -5.15% | - | |
| 1.06% | 4 M€ | +9.52% |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -1.91% | -2.00% | -31.59% | +335.35% | 2.73B | ||
| -3.14% | -5.61% | +7.64% | +94.63% | 117B | ||
| -3.61% | -4.53% | -30.20% | +4.24% | 71.22B | ||
| -0.19% | -3.59% | +70.58% | +145.03% | 38.94B | ||
| -0.67% | -2.25% | +22.93% | -33.02% | 27.45B | ||
| +0.71% | -0.76% | +50.51% | +9.37% | 23.61B | ||
| -1.86% | +3.88% | +8.26% | -30.77% | 22.56B | ||
| -6.93% | -7.47% | +324.00% | +800.00% | 14.07B | ||
| +2.27% | -1.38% | +182.80% | +242.29% | 14.29B | ||
| -1.65% | -23.34% | -11.68% | +36.62% | 11.65B | ||
| Average | -1.13% | -3.85% | +59.33% | +160.37% | 34.35B | |
| Weighted average by Cap. | -1.05% | -2.62% | +30.42% | +92.29% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | - | - |
| Net income | -111M -107M -101M -89.23M -159M -9.62B -176M -1.2B -447M -4B -415M -407M -16.88B | -168M -163M -154M -136M -241M -14.61B -267M -1.83B -679M -6.07B -631M -619M -25.64B |
| Net Debt | -418M -404M -382M -337M -598M -36.28B -664M -4.54B -1.69B -15.07B -1.57B -1.54B -63.67B | -499M -482M -455M -401M -714M -43.28B -792M -5.42B -2.01B -17.98B -1.87B -1.83B -75.94B |
More financial data
* Estimated data
Employees
50
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/02/25 | 43.23 $ | -1.91% | 173,531 |
| 10/02/25 | 44.07 $ | -2.20% | 329,512 |
| 07/02/25 | 45.06 $ | -4.35% | 285,518 |
| 06/02/25 | 47.11 $ | +1.03% | 292,103 |
| 05/02/25 | 46.63 $ | +5.71% | 392,966 |
Delayed Quote Nasdaq, February 11, 2025 at 09:00 pm
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
43.23USD
Average target price
78.00USD
Spread / Average Target
+80.43%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- MLTX Stock
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition